EDGAR·FLOW

MetaVia Inc. — Form 8-K

Filed November 17, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
MetaVia announced completion of the final patient visit in its Phase 1 Part 3A study of DA-1726 (a GLP-1/glucagon dual agonist), with the treatment period extended from 16 to 24 weeks at 48 mg weekly based on encouraging safety/tolerability. Part 3B interim data showed statistically significant 68.1% placebo-adjusted reduction in liver fat, 13.5% weight loss, and improved glycemic control. Full Part 3A and 3B data expected Q1 2027; Phase 2 study in MetALD/ALD planned for H2 2027 with up to 150 patients.
Why this rating

Clinical trial milestone in lead program is material for a $3M-market-cap biotech. Positive interim efficacy (68% liver-fat reduction) and decision to extend dosing strengthen near-term Phase 2 runway, reducing development risk—major value driver for pre-revenue clinical-stage firm.

Tradability signal
NO TRADE

No trade: only ~$72k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$1.26 ▲ 2.44%
at our read · unknown
$1.23
+10 min · unknown
$1.26 ▲ 2.85%
+30 min · unknown
$1.32 ▲ 7.32%
+1 hr · unknown
$1.31 ▲ 6.50%
+4 hrs · unknown
$1.23 ▲ 0.00%

The stock had already moved -2.38% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ MTVA · stock on Yahoo Finance ↗

See more from November 17, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.